Want to see GYRE full AI Analyst Report?
GYRE Stock Chart & Stats
$6.81
-$0.21(-2.15%)
At close: 4:00 PM EST
$6.81
-$0.21(-2.15%)
Day’s Range― - ―
52-Week Range$5.44 - $9.42
Previous CloseN/A
Volume104.17K
Average Volume (3M)102.52K
Market Cap
$764.81M
Enterprise Value$553.25M
Total Cash (Recent Filing)$49.81M
Total Debt (Recent Filing)$823.00K
Price to Earnings (P/E)―
Beta1.73
Next Earnings
Aug 18, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding111,488,846
10 Day Avg. Volume112,833
30 Day Avg. Volume102,519
Financial Highlights & Ratios
PEG Ratio-2.10
Price to Book (P/B)5.95
Price to Sales (P/S)5.41
P/FCF Ratio-3.50K
Enterprise Value/Market Cap0.72
Enterprise Value/Revenue4.73
Enterprise Value/Gross Profit4.97
Enterprise Value/Ebitda175.36
Forecast
1Y Price Target
$19.00Price Target Upside179.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.32
Revenue Forecast (FY)$102.30M
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth And Very High Gross MarginsTTM revenue growth near 39.5% combined with gross margins above 95% point to durable unit economics and expanding product adoption. High gross margins provide structural operating leverage as sales scale, supporting R&D and commercialization investment without eroding core profitability.
Conservative Balance Sheet: Very Low LeverageA very low debt load and sizable equity base provide multi-quarter financial flexibility to fund clinical programs, M&A, and commercialization. Low leverage reduces solvency risk and preserves optionality to pursue strategic investments or weather R&D timing variability without immediate external financing.
Pipeline Expansion Via Cullgen Integration And China OperationsIntegration of Cullgen’s degrader/DAC platform with Gyre’s China-based R&D, manufacturing and commercial capabilities materially broadens the pipeline and execution capacity. The cross-border footprint and leadership additions strengthen long-term development throughput and commercial reach across fibrosis, oncology, and inflammatory indications.
Bears Say
Recent Swing To Net Loss (profitability Volatility)The move from prior period profitability to a TTM net loss indicates unstable earnings delivery. Persistent margin swings increase the probability of external funding needs, constrain reinvestment timing for clinical programs, and raise execution risk for multi-quarter commercialization pushes.
Inconsistent Cash GenerationAlthough TTM operating and free cash flow are currently positive, cash generation has been uneven—large positive in 2023, negative in 2024, near-breakeven in 2025. This volatility undermines predictable funding for R&D and commercialization and increases reliance on capital markets or asset-level monetization.
Capital-structure Changes And Dilution RiskThe acquisition introduced a new preferred-stock class and assumed Cullgen incentive plans, changing voting and conversion dynamics. These structural capital changes elevate potential dilution, can shift governance balances, and may pressure per-share economics as the company funds expanded development and integration.
Gyre Therapeutics News
GYRE FAQ
What was Gyre Therapeutics’s price range in the past 12 months?
Gyre Therapeutics lowest stock price was $5.44 and its highest was $9.42 in the past 12 months.
What is Gyre Therapeutics’s market cap?
Gyre Therapeutics’s market cap is $764.81M.
When is Gyre Therapeutics’s upcoming earnings report date?
Gyre Therapeutics’s upcoming earnings report date is Aug 18, 2026 which is in 37 days.
How were Gyre Therapeutics’s earnings last quarter?
Gyre Therapeutics released its earnings results on May 07, 2026. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.073 by -$0.027.
Is Gyre Therapeutics overvalued?
According to Wall Street analysts Gyre Therapeutics’s price is currently Undervalued.
Does Gyre Therapeutics pay dividends?
Gyre Therapeutics pays a Quarterly dividend of $3.6 which represents an annual dividend yield of N/A. See more information on Gyre Therapeutics dividends here
What is Gyre Therapeutics’s EPS estimate?
Gyre Therapeutics’s EPS estimate is -0.06.
How many shares outstanding does Gyre Therapeutics have?
Gyre Therapeutics has 111,488,846 shares outstanding.
What happened to Gyre Therapeutics’s price movement after its last earnings report?
Gyre Therapeutics reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.073. Following the earnings report the stock price went down -12.065%.
Which hedge fund is a major shareholder of Gyre Therapeutics?
Currently, no hedge funds are holding shares in GYRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Gyre Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$19.00 (179.00% Upside)
$19.00 (179.00% Upside)
Insider Transactions
Sold Shares
Worth $869.9K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.79%
12-Months-Change
Fundamentals
Return on Equity
-6.27%
Trailing 12-Months
Asset Growth
24.83%
Trailing 12-Months
Company Description
Gyre Therapeutics
Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.
GYRE Stock 12 Month Forecast
Average Price Target
$19.00
▲(179.00% Upside)
Technical Analysis
Ownership Overview
60.35% Insiders
1.39% Mutual Funds
<0.01% Other Institutional Investors
36.64% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---